Biogen filed a lawsuit against a New York life sciences company over alleged patent infringements related to the experimental Alzheimer’s disease treatment aducanumab.
Powered by Xconomy, November 2019’s What’s Next in Neuroscience Therapies event brought together scientists, entrepreneurs and biotech executives at the Hyatt Regency San Francisco to discuss their work developing next-generation neuroscience therapies and technologies in areas such as spinal-cord injuries, precision mental health, dementia and Alzheimer’s disease.
Roche is testing the company’s “brain shuttle” in humans, with the Swiss drugmaker hoping to rejuvenate the theory that removing amyloid plaques from the brains of patients with Alzheimer’s disease will prove effective despite repeated failures.
Allergan will pay $750 million to settle a class action lawsuit from a group of direct purchasers of the Alzheimer’s disease therapy Namenda in a resolution to the litigation that was set to face trial.
Pfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.
Here are seven trends most likely to be hitting the news cycle in 2019 according to BioSpace.
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found.
Researchers in Japan and Australia say they have made important progress in developing a blood test that could in future help doctors detect who might go on to get Alzheimer’s disease.
Pfizer released an update of the company’s pipeline, including eight different discontinued projects in the field of neuroscience.
Eisai Inc. and Boston University School of Medicine have formed a research collaboration to study the effects of Alzheimer’s disease-associated genetic variants on the behavior of brain cells, called microglia.
